

Resource Summary Report

Generated by [NIF](#) on Jul 28, 2026

CD19

RRID:AB_394495

Type: Antibody

Proper Citation

BD Biosciences Cat# 552854, RRID:AB_394495

Antibody Information

URL: http://antibodyregistry.org/AB_394495

Proper Citation: BD Biosciences Cat# 552854, RRID:AB_394495

Target Antigen: CD19

Host Organism: rat

Clonality: monoclonal

Comments: Flow cytometry, Intracellular staining (flow Cytotoxicityometry)

Antibody Name: CD19

Description: This monoclonal targets CD19

Target Organism: mouse

Antibody ID: AB_394495

Vendor: BD Biosciences

Catalog Number: 552854

Record Creation Time: 20250820T063036+0000

Record Last Update: 20250821T001849+0000

Ratings and Alerts

No rating or validation information has been found for CD19.

No alerts have been found for CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. *Cancer cell*.

Sheban F, et al. (2025) ZEB2 is a master switch controlling the tumor-associated macrophage program. *Cancer cell*, 43(7), 1227.

Phongbunchoo Y, et al. (2024) YY1-mediated enhancer-promoter communication in the immunoglobulin γ locus is regulated by MSL/MOF recruitment. *Cell reports*, 43(7), 114456.

Wenzek C, et al. (2024) Lack of canonical thyroid hormone receptor γ signaling changes regulatory T cell phenotype in female mice. *iScience*, 27(8), 110547.

Chen J, et al. (2024) Intestinal microbiota imbalance resulted by anti-Toxoplasma gondii immune responses aggravate gut and brain injury. *Parasites & vectors*, 17(1), 284.

Cao S, et al. (2024) Glycosylation-modified antigens as a tolerance-inducing vaccine platform prevent anaphylaxis in a pre-clinical model of food allergy. *Cell reports. Medicine*, 5(1), 101346.

Montégut L, et al. (2024) Acyl-coenzyme A binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance. *Molecular cancer*, 23(1), 187.

Pelgrom LR, et al. (2023) QUAS-R: An SLC1A5-mediated glutamine uptake assay with single-cell resolution reveals metabolic heterogeneity with immune populations. *Cell reports*, 42(8), 112828.

Chen X, et al. (2023) Pregnancy-induced changes to the gut microbiota drive macrophage pyroptosis and exacerbate septic inflammation. *Immunity*, 56(2), 336.

Yao H, et al. (2023) A MYC-controlled redox switch protects B lymphoma cells from EGR1-dependent apoptosis. *Cell reports*, 42(8), 112961.

Martin-Martin I, et al. (2022) Aedes aegypti sialokinin facilitates mosquito blood feeding and modulates host immunity and vascular biology. *Cell reports*, 39(2), 110648.

Wiede F, et al. (2022) PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. *Cancer discovery*, 12(3), 752.

Kinkel SA, et al. (2022) Epigenetic modifier SMCHD1 maintains a normal pool of long-term hematopoietic stem cells. *iScience*, 25(7), 104684.

Quast I, et al. (2022) Interleukin-21, acting beyond the immunological synapse, independently controls T follicular helper and germinal center B cells. *Immunity*, 55(8), 1414.

Palma C, et al. (2021) Caloric Restriction Promotes Immunometabolic Reprogramming Leading to Protection from Tuberculosis. *Cell metabolism*, 33(2), 300.

Kong IY, et al. (2020) Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation. *Cell reports*, 33(3), 108290.

Lalwani A, et al. (2019) ? Cell Hypoxia-Inducible Factor-1? Is Required for the Prevention of Type 1 Diabetes. *Cell reports*, 27(8), 2370.

Vono M, et al. (2019) Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers. *Cell reports*, 28(7), 1773.

Francesconi M, et al. (2019) Single cell RNA-seq identifies the origins of heterogeneity in efficient cell transdifferentiation and reprogramming. *eLife*, 8.

Marcandalli J, et al. (2019) Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. *Cell*, 176(6), 1420.